Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
August 2013 Volume 6 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
August 2013 Volume 6 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells

  • Authors:
    • Ying Liu
    • Ying Dong
    • Bo Zhang
    • Yong‑Xian Cheng
  • View Affiliations / Copyright

    Affiliations: The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech and BioMedicine and Division of Life Sciences, Shenzhen Graduate School, Tsinghua University, Shenzhen, Guangdong 518055, P.R. China, Department of Oncology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P.R. China, State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, Yunnan 650204, P.R. China
  • Pages: 556-558
    |
    Published online on: May 30, 2013
       https://doi.org/10.3892/ol.2013.1370
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

6‑O‑angeloylplenolin (6‑OAP) is a sesquiterpene lactone agent that has been previously demonstrated to inhibit the growth of multiple myeloma (MM) cells through mitotic arrest with accumulated cyclin B1. In the present study, the levels of apoptosis were analyzed in dexamethasone‑sensitive (MM.1S), dexamethasone‑resistant (U266) and chemotherapy‑sensitive (RPMI 8226) myeloma cell lines. Enhanced apoptosis was identified following a 48‑h incubation with 6‑OAP (0‑10 µM) that induced a dose‑dependent decrease in pro‑casp‑3 and the cleavage of its substrate, anti‑poly (ADP-ribose) polymerase (PARP). In addition, time-dependent cleavage of PARP was also detected in U266 and MM.1S cells. The mechanism of 6‑OAP cytotoxicity in all cell lines was associated with the induction of apoptosis with the presence of cleaved caspase‑3 and PARP. In conclusion, 6‑OAP‑induced apoptosis is caspase‑dependent. These observations are likely to provide a framework for future studies of 6‑OAP therapy in MM.

Introduction

Multiple myeloma (MM) or plasma cell myeloma is a malignant disorder characterized by the accumulation of differentiated B cells (plasma cells). The incompletely differentiated plasma cells are characterized by deregulated apoptosis (1). The treatment of MM remains unsatisfactory and new agents that specifically target key signaling pathways required for myeloma growth or survival are urgently required.

6-O-angeloylplenolin (6-OAP; Fig 1A) is a sesquiterpene lactone isolated from Centipeda minima that has been studied in hematological and solid forms of cancer and has been revealed to exhibit activity without significant toxicity (2–4). The results of our preliminary study demonstrated that 6-OAP inhibits the proliferation of human MM cells by inducing the arrest of mitosis and inhibiting specific key pathways (5). However, whether 6-OAP-induced mitosis arrest and pathway inhibition are followed by apoptosis requires further study. Therefore, the aim of the present study was to investigate the apoptotic effect of 6-OAP against human myeloma cells.

Figure 1.

6-OAP induces apoptosis in multiple myeloma (MM) cells, as detected by DNA fragmentation assay. (A) Chemical structure of 6-OAP. (B) U266 and MM.1S cells were treated with 6-OAP at the indicated concentrations for 48 h and DNA fragmentation was analyzed. 6-OAP, 6-O-angeloylplenolin.

Materials and methods

Reagents

6-OAP with a purity ≤99.5% was extracted from Centipeda minima (L.) as described previously (4). The 6-OAP was then dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to produce a stock solution of 10−2 M, which was stored at −20°C.

Cell culture

MM.1S, U266 and RPMI 8226 human MM cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 medium supplemented with 10% (for U266) or 15% (for RPMI 8226 and MM.1S) fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT, USA) and incubated in a humidified atmosphere with 5% CO2 at 37°C.

Patient samples

CD138+ cells from a single patient with MM were isolated with informed consent from bone marrow (BM) mononuclear cells using positive immunomagnetic column separation (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The purity of the CD138+ cells was >97% as determined by flow cytometry. This study was approved by the ethics committee of Shenzhen Graduate School, Tsinghua University, Shenzhen, China.

DNA fragmentation

The MM cells were collected and lysed in 0.5 ml lysis buffer containing 10 mM Tris (pH 8.0), 10 mM EDTA and 0.05% Triton X-100. The lysate was centrifuged, RNase (0.2 mg/ml) was added and the lysate was incubated for 30 min at 37°C. Proteinase K (0.1 mg/ml) and sodium dodecyl sulfate (SDS; final concentration 1%) were added, followed by incubation at 50°C for 16 h. DNA was extracted with phenol/chloroform and then chloroform, prior to being precipitated with ethanol and sodium acetate and electrophoresed on 1.5% agarose gels, and then visualized with ethidium bromide (EB) staining.

Flow cytometric assays for Annexin-V (AV)

Cell apoptosis was evaluated by AV detection using an AV-FITC kit (BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer’s instructions.

Western blot

Cell pellets were lysed in RIPA buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40, 1 mM DTT, 1 mM NaF, 1 mM sodium vanadate and a protease inhibitor cocktail (Sigma-Aldrich). Protein extracts were quantitated, loaded on 8–12% SDS-polyacrylamide gels, electrophoresed and then transferred to a nitrocellulose membrane (Whatman plc, Maidstone, Kent). The membrane was incubated with primary antibody, washed and incubated with horseradish peroxidase-conjugated secondary antibody. Detection was performed using a chemiluminescent western detection kit (Cell Signaling Technology, Inc., Danvers, MA, USA). The antibodies used were anti-caspase-3, anti-poly (ADP-ribose) polymerase (PARP; Cell Signaling Technology, Inc.) and anti-β-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).

Statistical analysis

All experiments were repeated at least three times and the data are presented as the mean ± SD unless noted otherwise. P<0.05 was considered to indicate a statistically significant difference.

Results

6-OAP induces apoptosis in MM cells

The levels of apoptosis were analyzed using the DNA fragmentation assay in dexamethasone-sensitive (MM.1S) and dexamethasone-resistant (U266) myeloma cell lines treated with 6-OAP. As demonstrated in Fig. 1B, marked DNA ladders were observed in MM.1S and U266 cells treated with 6-OAP, indicative of apoptosis detection.

In addition, AV staining was conducted to assess apoptosis in U266 and chemotherapy-sensitive RPMI 8226 cell lines treated with 6-OAP. Using flow cytometry, 7.5 μM 6-OAP was identified to induce apoptosis at a ratio of 28 and 46% in U266 and RPMI 8226 cells, respectively (Fig. 2). These results indicate that 6-OAP induces apoptosis in MM cells.

Figure 2.

6-OAP induces apoptosis in multiple myeloma (MM) cells detected by Annexin V staining. U266 and RPMI 8226 cells were treated with 6-OAP for 24 h. Annexin V staining was determined by flow cytometry. 6-OAP, 6-O-angeloylplenolin.

6-OAP-induced apoptosis in MM cells is caspase-dependent

The apoptotic pathways that ultimately lead to the activation of effector caspases (casp-3, -2 and -7) and the cleavage of PARP have been characterized in MM (6). Therefore, a western blot analysis was used to detect the activation of the casp-3 effector caspase and its substrate, PARP, in the MM cells. 6-OAP was demonstrated to induce a significant dose-dependent decrease in pro-casp-3 and the cleavage of its substrate, PARP, in the three cell lines, indicating the activation of casp-3 (Fig. 3A). 6-OAP also markedly induced the cleavage of PARP in a time-dependent manner in the U266 and MM.1S cells (Fig. 3B). In addition, the expression of pro-casp-3 and the cleavage of PARP was investigated in CD138+ primary cells isolated from a single MM patient (Fig. 3C). The results of the western blot analysis demonstrated that 6-OAP significantly induces the activation of casp-3. These observations indicate that 6-OAP induces caspase-dependent apoptosis in MM cells.

Figure 3.

6-OAP induces caspase-dependent apoptosis of multiple myeloma (MM) cells. (A) U266, MM.1S and RPMI 8226 cells were treated with 6-OAP for 48 h and lyzed, then extracts were subjected to western blot analysis. (B) U266 cells (upper) or MM.1S cells (lower) were treated with 6-OAP for the indicated time points. (C) CD138+ primary cells isolated from 1 MM patient were treated with or without 6-OAP for 24 h. Total cell lysates were subjected to western blot analysis using antibodies against casp-3, PARP and β-actin. 6-OAP, 6-O-angeloylplenolin; casp-3, caspase-3; PARP, anti-poly (ADP-ribose) polymerase.

Discussion

The natural agent, 6-OAP, was initially demonstrated to exhibit anti-bacterial and anti-protozoal activities (7–9). However, more recently, studies have demonstrated an anti-tumor activity for 6-OAP in solid tumors and hematological malignancies (2–4). Our previous observations found that 6-OAP induces the arrest of mitosis in MM cells by the activation of the spindle assembly checkpoint and the accumulation of cyclin B1. In addition, 6-OAP was identified to inhibit the Jak2/Stat3 and Akt signaling pathways, thereby blocking the facilitation of the BM microenvironment on the MM cells. 6-OAP has also been found to induce marked inhibition of NF-κB in MM cells (5). However, to date, no studies have determined whether the inhibitory effects of 6-OAP on the cell cycle and certain signal pathways ultimately result in apoptosis. Therefore, in the present study, the effect of 6-OAP on apoptosis in MM cells was analyzed.

Apoptosis is an active process that ultimately leads to the activation of endonucleases and the cleavage of DNA into fragments of 180–200 bp. The extrinsic and intrinsic apoptotic pathways that ultimately lead to activation of effector caspases (casp-3, -2 and -7) have also been characterized (10,11). The present study demonstrated that 6-OAP-treated MM cells exhibited evident DNA fragments of 180–200 bp (Fig. 1B), indicating that 6-OAP induces apoptosis in MM cells. The activation of the effector caspases was also analyzed and 6-OAP was found to induce casp-3 activation, followed by PARP cleavage in various MM cell lines (Fig. 3), indicating that 6-OAP induces caspase-dependent apoptosis in MM cells. In conclusion, 6-OAP induces growth inhibition in human MM cells using a number of different mechanisms, including the arrest of mitosis and the inhibition of certain signaling pathways. These different mechanisms ultimately lead to caspase-dependent apoptotic cell death.

Acknowledgements

This study was supported, in part, by the National Natural Science Foundation of China (No. 81101835) and the Foundation of Zhejiang Provincial Education Department (No. Y200804683).

References

1. 

Chauhan D and Anderson KC: Apoptosis in multiple myeloma: therapeutic implications. Apoptosis. 6:47–55. 2001. View Article : Google Scholar : PubMed/NCBI

2. 

Changlong L, Hezhen W, Yongping H, Yanfang Y, Yanwen L and Jianwen L: 6-O-Angeloylenolin induces apoptosis through a mitochondrial/caspase and NF-kappaB pathway in human leukemia HL60 cells. Biomed Pharmacother. 62:401–409. 2008. View Article : Google Scholar : PubMed/NCBI

3. 

Su M, Chung HY and Li Y: 6-O-Angeloylenolin induced cell-cycle arrest and apoptosis in human nasopharyngeal cancer cells. Chem Biol Interact. 189:167–176. 2011. View Article : Google Scholar : PubMed/NCBI

4. 

Ding LF, Liu Y, Liang HX, Liu DP, Zhou GB and Cheng YX: Two new terpene glucosides and antitumor agents from Centipeda minima. J Asian Nat Prod Res. 11:732–736. 2009. View Article : Google Scholar : PubMed/NCBI

5. 

Liu Y, Chen XQ, Liang HX, Zhang FX, Zhang B, Jin J, Chen YL, Cheng YX and Zhou GB: Small compound 6-o-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. PLoS One. 6:e219302011. View Article : Google Scholar : PubMed/NCBI

6. 

Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:3071–3076. 2001.PubMed/NCBI

7. 

Taylor RS and Towers GH: Antibacterial constituents of the Nepalese medicinal herb, Centipeda minima. Phytochemistry. 47:631–634. 1998. View Article : Google Scholar : PubMed/NCBI

8. 

Francois G, Passreiter CM, Woerdenbag HJ and Van LM: Antiplasmodial activities and cytotoxic effects of aqueous extracts and sesquiterpene lactones from Neurolaena lobata. Planta Med. 62:126–129. 1996. View Article : Google Scholar : PubMed/NCBI

9. 

Schwikkard S and van Heerden FR: Antimalarial activity of plant metabolites. Nat Prod Rep. 19:675–692. 2002.PubMed/NCBI

10. 

Nicholson DW: Caspase structure, proteolytic substrates and function during apoptotic cell death. Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI

11. 

Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Liu Y, Dong Y, Zhang B and Cheng YX: Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells. Oncol Lett 6: 556-558, 2013.
APA
Liu, Y., Dong, Y., Zhang, B., & Cheng, Y. (2013). Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells. Oncology Letters, 6, 556-558. https://doi.org/10.3892/ol.2013.1370
MLA
Liu, Y., Dong, Y., Zhang, B., Cheng, Y."Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells". Oncology Letters 6.2 (2013): 556-558.
Chicago
Liu, Y., Dong, Y., Zhang, B., Cheng, Y."Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells". Oncology Letters 6, no. 2 (2013): 556-558. https://doi.org/10.3892/ol.2013.1370
Copy and paste a formatted citation
x
Spandidos Publications style
Liu Y, Dong Y, Zhang B and Cheng YX: Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells. Oncol Lett 6: 556-558, 2013.
APA
Liu, Y., Dong, Y., Zhang, B., & Cheng, Y. (2013). Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells. Oncology Letters, 6, 556-558. https://doi.org/10.3892/ol.2013.1370
MLA
Liu, Y., Dong, Y., Zhang, B., Cheng, Y."Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells". Oncology Letters 6.2 (2013): 556-558.
Chicago
Liu, Y., Dong, Y., Zhang, B., Cheng, Y."Small compound 6‑O‑angeloylplenolin induces caspase‑dependent apoptosis in human multiple myeloma cells". Oncology Letters 6, no. 2 (2013): 556-558. https://doi.org/10.3892/ol.2013.1370
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team